[1]傅 卫,赵 琨.中国卫生技术评估的发展与挑战[J].卫生经济研究,2019,(03):3-5.
　FU Wei,ZHAO Kun.Development and Challenges of China's Health Technology Assessment[J].Journal Press of Health Economics Research,2019,(03):3-5.
点击复制

中国卫生技术评估的发展与挑战

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
期数:
2019年03期
页码:
3-5
栏目:
聚焦医改
出版日期:
2019-02-28

文章信息/Info

Title:
Development and Challenges of China's Health Technology Assessment
作者:
傅 卫1; 2; 赵 琨1; 2
1.国家卫生健康委员会卫生发展研究中心，北京 100091
2.国家药物与卫生技术综合评价中心，北京 100091
Author(s):
FU Wei; ZHAO Kun
National Health Commission Health Development Research Center，Beijing 100091，China
关键词:
卫生技术评估; 循证决策
Keywords:
health technology assessment; evidence-based decision making
分类号:
R19
文献标志码:
A
摘要:
近年来，我国卫生技术评估发展迅速，在药品、大型设备、临床检验和诊治技术、筛查和疫苗等领域进行了广泛的实践与探索，初步形成各类技术评估方法和指南，已逐渐成为决策者的决策分析工具。随着新技术不断涌现，要健全卫生技术评估的体系建设、完善评估方法和评估标准、壮大评估队伍、提升技术能力，平稳推进卫生技术评估工作。
Abstract:
In recent years，China's health technology assessment has developed rapidly. It has carried out extensive practice and exploration in the fields of medicines，large equipment， clinical testing and diagnosis and treatment technologies，screening and vaccines，and has initially formed various technical assessment methods and guidelines，which have gradually become decision-making tool. As new technologies continue to emerge，it is necessary to improve the system construction of health technology assessment，improve evaluation methods and evaluation standards，strengthen the evaluation team，enhance technical capabilities，and steadily promote health technology assessment.

参考文献/References:

[1] Goodman, C.Rapid Reviews at the HTAi Meeting. HTAi Annual Conference. Bilbao, Spain. 2012-06-24.
[2] Watt,et al. Rapid reviews versus full systematic reviews: An inventory of current methods and practice in health technology assessment. International Journal of Technology Assessment in Health Care, 2008,24(2): 133-139.
[3] Hailey, D.A preliminary survey on the influence of rapidhealth technology assessments. International Journal of Technology Assessment in Health Care, 2009,25(3):415-418.
[4] Khangura, S,et al. Evidence summaries: the evolution of a rapid review approach. In Khangura et al. Systematic Reviews 2012, 1:10.
[5] 郭武栋，刘莹，赵琨，等.基于7所医院数据的血液透析与腹膜透析成本比较研究[J].中国医院管理，2018(6):50-51，54.
[6] 隋宾艳， 金承刚，邱英鹏，等.内窥镜手术器械控制系统辅助手术成本效果系统评述[J].卫生经济研究，2018(6):6-9.
[7] 史黎炜，邱英鹏，肖月，等. 内窥镜手术器械控制系统辅助手术的成本测算[J].卫生经济研究，2018(6):10-12.
[8] 邱英鹏，肖月，史黎炜，等.内窥镜手术器械控制系统辅助治疗的成本效果分析[J].卫生经济研究，2018(6):10-12.
[9] 肖月，史黎炜，邱英鹏，等. 内窥镜手术器械控制系统应用的预算影响分析[J].卫生经济研究，2018(6):15-18.

相似文献/References:

[1]黄 理,路 云,段承阿鑫.卫生技术评估在高值医用耗材供应保障中的应用价值及其实现[J].卫生经济研究,2018,(10):10.
　HUANG Li,LU Yun,DUAN Cheng-a-xin.The Application Value and Its Realization of Health Technology Assessment in the Supply Security of High-value Medical Consumables[J].Journal Press of Health Economics Research,2018,(03):10.
[2]金春林,王海银,孙 辉,等.价值医疗的概念、实践及其实现路径[J].卫生经济研究,2019,(02):6.
　JIN Chun-lin,WANG Hai-yin,SUN Hui,et al.The Concept, Progress and Practice Path of Value-based healthcare[J].Journal Press of Health Economics Research,2019,(03):6.
[3]张 宸,金秋晨,陈永法.儿童药卫生技术评估的特殊性——以英国NICE儿童药评估为例[J].卫生经济研究,2021,38(11):51.
　ZHANG Chen,JIN Qiu-chen,CHEN Yong-fa.Particularity of Health Technology Assessment for Children's Drug——Taking NICE Children's Drug Assessment as an Example[J].Journal Press of Health Economics Research,2021,38(03):51.
[4]金秋晨,张 宸,陈永法.抗肿瘤药物联合疗法价值归因探索[J].卫生经济研究,2023,40(10):74.
　JIN Qiuchen,ZHANG Chen,CHEN Yongfa.Study on the Value Attribution of Antitumor Drug Combination Therapy[J].Journal Press of Health Economics Research,2023,40(03):74.
[5]郑王彪,郑 超,孙 强.医保药品目录动态调整的国际经验与启示[J].卫生经济研究,2023,40(12):62.
　ZHENG Wangbiao,ZHENG Chao,SUN Qiang.International Experience and Enlightenment on the Dynamic Adjustment of Medical Insurance Drug Catalog[J].Journal Press of Health Economics Research,2023,40(03):62.
[6]杨婷婷,薛允莲,吴伟旋,等.高值医用耗材评价的难点分析与方法优化 ——基于多维度分析[J].卫生经济研究,2025,42(11):54.
　YANG Tingting,XUE Yunlian,WU Weixuan,et al.Analysis of Challenges and Optimization of Methods in the Evaluation of High-Value Medical Consumables ——Based on a Multi-Dimensional Analysis[J].Journal Press of Health Economics Research,2025,42(03):54.
[7]骆依静,许 军,陈星伟,等.药品价值评价的全球趋势与中国实践研究[J].卫生经济研究,2026,43(02):47.
　LUO Yijing,XU Jun,CHEN Xingwei,et al.Research on Global Trends and Chinese Practice in Drug Value Assessment[J].Journal Press of Health Economics Research,2026,43(03):47.
[8]崔雅婷,王俊斐,徐彩花,等.全球卫生技术评估研究热点与发展趋势[J].卫生经济研究,2026,43(03):6.
　CUI Yating,WANG Junfei,XU Caihua,et al.Analysis of Research Hotspots and Development Trends in Health Technology Assessment[J].Journal Press of Health Economics Research,2026,43(03):6.
[9]夏雨婷,唐文熙.生命周期卫生技术评估的国际实践与启示[J].卫生经济研究,2026,43(06):25.
　XIA Yuting,TANG Wenxi.International Practices and Implications of Lifecycle Health Technology Assessment[J].Journal Press of Health Economics Research,2026,43(03):25.
[10]徐志浩,王 健,谭佳龙.医保决策中真实世界数据的应用实践与启示 ——以NICE药品准入评估中的决策调整因子为例[J].卫生经济研究,2026,43(06):34.
　XU Zhihao,WANG Jian,TAN Jialong.Practical Applications and Insights of Real-World Data in Health Insurance Decision-Making ——Taking Decision Modifiers of Drug Access Assessment in NICE as an Example[J].Journal Press of Health Economics Research,2026,43(03):34.

更新日期/Last Update: 2019-02-28